Lisa Astor

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

The FDA has granted a fast track designation to lasofoxifene for use as a treatment of female patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations.

About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

Combining lenvatinib and pembrolizumab led to a 25% overall response rate in patients with urothelial carcinoma and was associated with a manageable safety profile.

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

The frequency of hereditary mutations that convey an increased risk of ovarian cancer suggests that many cases of the disease are preventable.

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

Molecular pathologists have helped to advance translational research significantly for lung cancer over the past 10 years; nowhere is that more obvious than in EGFR-mutant non-small cell lung cancer.

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.

Building on the success of molecularly targeted drugs aimed at relatively small subsets of patients, lung cancer researchers are increasingly aiming at the MET oncogene.

Although there has been reluctance among oncology researchers to administer immunotherapy to patients with HIV who develop cancer, early signals from a small clinical trial suggest that such a strategy may be safe in certain settings.

The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.

A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.